Point72 Asset Management L.P. Boosts Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Point72 Asset Management L.P. grew its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 35.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 633,100 shares of the company's stock after purchasing an additional 165,300 shares during the period. Point72 Asset Management L.P. owned approximately 2.12% of Silence Therapeutics worth $4,356,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of SLN. JPMorgan Chase & Co. bought a new stake in Silence Therapeutics during the fourth quarter worth about $26,000. Barclays PLC raised its holdings in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Silence Therapeutics during the fourth quarter valued at approximately $69,000. Virtus ETF Advisers LLC raised its holdings in shares of Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after purchasing an additional 6,098 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in shares of Silence Therapeutics during the 4th quarter worth $113,000. Institutional investors own 98.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Chardan Capital reduced their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, May 9th. BMO Capital Markets cut their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. The Goldman Sachs Group cut their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research note on Friday, May 9th. Finally, Morgan Stanley cut their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Stock Performance

SLN stock traded up $0.22 during trading on Friday, hitting $5.06. 66,744 shares of the company's stock traded hands, compared to its average volume of 301,635. Silence Therapeutics plc has a 52 week low of $1.97 and a 52 week high of $22.47. The business has a fifty day simple moving average of $3.44 and a 200 day simple moving average of $5.49. The stock has a market capitalization of $151.45 million, a price-to-earnings ratio of -3.22 and a beta of 1.20.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. Research analysts forecast that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.